Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Cyclin D1 mRNA 3' untranslated region (3' UTR) is a critical regulatory segment of the CCND1 transcript that governs mRNA stability, localization, and translation efficiency (Wiener & Goss, 2006, Genes Chromosomes Cancer). It contains multiple regulatory elements, including AU-rich elements (AREs) and binding sites for microRNAs (miRNAs) such as the miR-15/16 family, which normally promote mRNA degradation or inhibit translation (Deshpande et al., 2009, Blood). In various malignancies, particularly mantle cell lymphoma and breast cancer, the 3' UTR is frequently truncated or altered through alternative splicing or genomic deletions (Bentley et al., 2019, Journal of Biological Chemistry). These alterations remove negative regulatory elements, leading to increased mRNA stability, constitutive Cyclin D1 protein overexpression, and uncontrolled cell cycle progression from G1 to S phase (Lebailly et al., 2010, Haematologica). Consequently, the 3' UTR is an attractive therapeutic target for RNA-based interventions, including antisense oligonucleotides (ASOs), siRNA, and miRNA mimics designed to restore translational repression or induce transcript degradation (Knudsen et al., 2006, Molecular Cancer Therapeutics). Emerging research also explores small molecules that can bind to specific secondary structures, such as G-quadruplexes, within the 3' UTR to modulate Cyclin D1 expression (Saha et al., 2017, Scientific Reports).
Induction of mRNA degradation through RNase H recruitment or the RNA-induced silencing complex (RISC), and inhibition of translation by blocking ribosomal access or stabilizing repressive RNA secondary structures.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclin D1 mRNA 3' untranslated region (CCND1 mRNA 3' UTR).